AB008. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
Abstract
Background There is no standard second-line treatment for patients with platinum refractory advanced B3-Thymoma (T) and thymic carcinoma (TC). In this population, the PECATI trial testing lenvatinib plus pembrolizumab met its primary endpoint, with 5-month progression-free survival (PFS) of 88.0% (90% CI: 73.5–94.8). Methods This single-arm, phase 2 trial enrolled patients with advanced or unresectable B3-T and TC, without autoimmune disorders and with measurable lesions by RECIST v.1.1 that have progressed following at least one platinum-based chemotherapy. Treatment consisted of lenvatinib (20 mg orally daily) plus pembrolizumab (200 mg iv infusion once every 3 weeks) in 3-week cycles until disease progression, unacceptable toxicity, or a maximum of 35 cycles. Previous treatment with immunotherapy or sunitinib was not allowed. Results From 09/2021 to 02/2024, 43 patients were enrolled. Median age 57 years (33–81); 84% had a TC; Masaoka Koga IVA/B (35%/65%) with ≥3 metastatic sites in 51% of patients (including 37% with liver metastases), and 44.2% received ≥2 prior lines for advanced disease. PD-L1 expression (22C3, n=32) <1%: 53%, 1-49%: 31%; ≥50%: 16%. After a median follow-up of 24.6 months, median PFS was 22.1 months (95% CI: 10.9–25.1), median overall survival (OS) was 40.2 months (95% CI: 19.1-not estimated), and the 36-monht OS rate was 53.0%. In TC, the median PFS and OS were 21.5 and 40.2 months, respectively. Confirmed objective response rate was 25.6% and median duration of response was 19.8 months (95% CI: 6.1-not estimated). Ten patients (23.3%) completed 2 years of treatment. Grade ≥3 treatment-related adverse events occurred in 46.5% of patients and led to treatment discontinuation in 18.6%. Two (4.7%) non-treatment-related grade 5 events were reported. Grade ≥3 immune-related adverse events occurred in six (14%) patients. No meaningful differences in the toxicity profile were observed between patients with B3-T and TC. Conclusions Final PECATI results support lenvatinib plus pembrolizumab as a potential standard treatment for pre-treated advanced B3-T and TC. Toxicity profile was manageable but close monitoring is advised.